- Home
- IMRN
IMRN
Immuron Limited
as 07-26-2024 4:00pm EST
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
| Founded: | 1994 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | 13.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 9.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.48 - $5.96 | Next Earning Date: | 07-23-2024 |
| Revenue: | $2,433,088 | Revenue Growth: | 219.95% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Immuron Limited News
IMRN Breaking Stock News: Dive into IMRN Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
GlobeNewswire
11 days ago
Immuron announces record Travelan® sales globally, Australia and USA
MT Newswires
23 days ago
Immuron Files for Mixed-Shelf Offering; Plans to Raise $2M Through At-The-Market Equity Sale
MT Newswires
24 days ago
Immuron Requests Meeting With FDA for Potential Colon Infection Therapy
GlobeNewswire
25 days ago
Immuron requests pre-IND meeting for IMM-529 with FDA filing
GlobeNewswire
a month ago
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
GlobeNewswire
2 months ago
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
GlobeNewswire
2 months ago
Immuron Board Changes
Compare IMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMRN Immuron Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.